Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin M Greenberg

Showing results (101-110 of 133) with videos related to

Pageof 14
Sort By:
Frontiers in Immunology|November 17, 2022
Translation suppression underlies the restrained COVID-19 mRNA vaccine response in the high-risk immunocompromised groupKangsan Kim, Madhusudhanan Narasimhan, Lenin Mahimainathan, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 20, 2023
Disease associations of excessive daytime sleepiness in multiple sclerosis: A prospective studyPeter V Sguigna, Sabeen Toranian, Lauren M Tardo, et al.
Archives of Neurology|August 11, 2010
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?Clemens Warnke, Til Menge, Hans-Peter Hartung, et al.
Nature Communications|May 18, 2018
A whole-genome sequence study identifies genetic risk factors for neuromyelitis opticaKarol Estrada, Christopher W Whelan, Fengmei Zhao, et al.
Journal of Pharmacy Practice|August 30, 2017
Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple SclerosisChristine Bell, James Anderson, Tanmoy Ganguly, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 6, 2025
Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension StudyJeffrey L Bennett, Kazuo Fujihara, Albert Saiz, et al.
Gene|July 15, 2015
MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencingWilliam H Rounds, Edward A Salinas, Tom B Wilks, et al.
Journal of the Neurological Sciences|October 3, 2012
Objective characterization of the relative afferent pupillary defect in MSPaul Blazek, Scott L Davis, Benjamin M Greenberg, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 31, 2025
Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension StudyJeffrey L Bennett, Kazuo Fujihara, Albert Saiz, et al.
Ebiomedicine|November 28, 2025
First-in-human high dose AAV9 intrathecal gene therapy for paediatric CLN7 disease: a phase 1, open-label, single ascending dose, non-randomised clinical trialBenjamin M Greenberg, Berge Minassian, Souad Messahel, et al.
Pageof 14

Showing results (101-110 of 133) with videos related to

Sort By:
Pageof 14
Frontiers in Immunology|November 17, 2022
Translation suppression underlies the restrained COVID-19 mRNA vaccine response in the high-risk immunocompromised groupKangsan Kim, Madhusudhanan Narasimhan, Lenin Mahimainathan, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 20, 2023
Disease associations of excessive daytime sleepiness in multiple sclerosis: A prospective studyPeter V Sguigna, Sabeen Toranian, Lauren M Tardo, et al.
Archives of Neurology|August 11, 2010
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?Clemens Warnke, Til Menge, Hans-Peter Hartung, et al.
Nature Communications|May 18, 2018
A whole-genome sequence study identifies genetic risk factors for neuromyelitis opticaKarol Estrada, Christopher W Whelan, Fengmei Zhao, et al.
Journal of Pharmacy Practice|August 30, 2017
Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple SclerosisChristine Bell, James Anderson, Tanmoy Ganguly, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 6, 2025
Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension StudyJeffrey L Bennett, Kazuo Fujihara, Albert Saiz, et al.
Gene|July 15, 2015
MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencingWilliam H Rounds, Edward A Salinas, Tom B Wilks, et al.
Journal of the Neurological Sciences|October 3, 2012
Objective characterization of the relative afferent pupillary defect in MSPaul Blazek, Scott L Davis, Benjamin M Greenberg, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 31, 2025
Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension StudyJeffrey L Bennett, Kazuo Fujihara, Albert Saiz, et al.
Ebiomedicine|November 28, 2025
First-in-human high dose AAV9 intrathecal gene therapy for paediatric CLN7 disease: a phase 1, open-label, single ascending dose, non-randomised clinical trialBenjamin M Greenberg, Berge Minassian, Souad Messahel, et al.
Pageof 14